Published in Science on August 13, 1999
Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc Natl Acad Sci U S A (2005) 2.95
A C. elegans model of nicotine-dependent behavior: regulation by TRP-family channels. Cell (2006) 2.68
Cocaine sensitization and reward are under the influence of circadian genes and rhythm. Proc Natl Acad Sci U S A (2002) 2.40
Influence of the period-dependent circadian clock on diurnal, circadian, and aperiodic gene expression in Drosophila melanogaster. Proc Natl Acad Sci U S A (2002) 2.33
A Drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants. Proc Natl Acad Sci U S A (2002) 1.74
Sleep disturbance as transdiagnostic: consideration of neurobiological mechanisms. Clin Psychol Rev (2010) 1.48
When clocks go bad: neurobehavioural consequences of disrupted circadian timing. PLoS Genet (2008) 1.41
Drosophila melanogaster as a model to study drug addiction. Hum Genet (2012) 1.39
Cycling behavior and memory formation. J Neurosci (2009) 1.37
A role for the circadian genes in drug addiction. Neuropharmacology (2008) 1.32
Implementing large-scale ENU mutagenesis screens in North America. Genetica (2004) 1.31
Changes in period mRNA levels in the brain and division of labor in honey bee colonies. Proc Natl Acad Sci U S A (2000) 1.28
Drosophila CLOCK is constitutively expressed in circadian oscillator and non-oscillator cells. J Biol Rhythms (2006) 1.25
The methamphetamine-sensitive circadian oscillator does not employ canonical clock genes. Proc Natl Acad Sci U S A (2009) 1.15
Lmo mutants reveal a novel role for circadian pacemaker neurons in cocaine-induced behaviors. PLoS Biol (2004) 1.15
Circadian modulation of dopamine receptor responsiveness in Drosophila melanogaster. Proc Natl Acad Sci U S A (2000) 1.15
Astrocytic control of synaptic transmission and plasticity: a target for drugs of abuse? Neuropharmacology (2008) 1.11
A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine. Psychopharmacology (Berl) (2008) 1.10
Circuit projection from suprachiasmatic nucleus to ventral tegmental area: a novel circadian output pathway. Eur J Neurosci (2008) 1.08
Flies, clocks and evolution. Philos Trans R Soc Lond B Biol Sci (2001) 1.08
Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci (2009) 1.08
Translational profiling of clock cells reveals circadianly synchronized protein synthesis. PLoS Biol (2013) 1.08
Cocaine modulates locomotion behavior in C. elegans. PLoS One (2009) 1.02
The role of mPer1 in morphine dependence in mice. Neuroscience (2005) 0.97
When brain clocks lose track of time: cause or consequence of neuropsychiatric disorders. Curr Opin Neurobiol (2011) 0.97
Clock genes running amok. Clock genes and their role in drug addiction and depression. EMBO Rep (2007) 0.96
A genomewide linkage scan of cocaine dependence and major depressive episode in two populations. Neuropsychopharmacology (2011) 0.96
The clock gene PER2 and sleep problems: association with alcohol consumption among Swedish adolescents. Ups J Med Sci (2010) 0.95
Drosophila, a genetic model system to study cocaine-related behaviors: a review with focus on LIM-only proteins. Neuropharmacology (2008) 0.95
Differential entrainment of a social rhythm in adolescent mice. Behav Brain Res (2008) 0.94
First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians. Behav Pharmacol (2010) 0.94
PER2 rs2304672 polymorphism moderates circadian-relevant reward circuitry activity in adolescents. Biol Psychiatry (2011) 0.93
Brain fatty acid binding protein (Fabp7) is diurnally regulated in astrocytes and hippocampal granule cell precursors in adult rodent brain. PLoS One (2008) 0.92
Cocainomics: new insights into the molecular basis of cocaine addiction. J Neuroimmune Pharmacol (2010) 0.92
Glial cell modulation of circadian rhythms. Glia (2010) 0.91
Assessment of genome and proteome profiles in cocaine abuse. Prog Brain Res (2006) 0.90
Time of day regulates subcellular trafficking, tripartite synaptic localization, and polyadenylation of the astrocytic Fabp7 mRNA. J Neurosci (2012) 0.90
Comparing the utility of homogeneous subtypes of cocaine use and related behaviors with DSM-IV cocaine dependence as traits for genetic association analysis. Am J Med Genet B Neuropsychiatr Genet (2013) 0.88
Circadian rhythms and addiction: mechanistic insights and future directions. Behav Neurosci (2014) 0.87
Quantitative trait loci for the monoamine-related traits heart rate and headless behavior in Drosophila melanogaster. Genetics (2001) 0.87
Differential regulation of the period genes in striatal regions following cocaine exposure. PLoS One (2013) 0.87
Circadian clock genes: effects on dopamine, reward and addiction. Alcohol (2015) 0.86
Review. Genetics of addictions: strategies for addressing heterogeneity and polygenicity of substance use disorders. Philos Trans R Soc Lond B Biol Sci (2008) 0.86
Increased consumption but not operant self-administration of ethanol in mice lacking the RIIbeta subunit of protein kinase A. Alcohol Clin Exp Res (2006) 0.86
Drug-sensitive reward in crayfish: an invertebrate model system for the study of SEEKING, reward, addiction, and withdrawal. Neurosci Biobehav Rev (2010) 0.84
Methamphetamine and dopamine receptor D1 regulate entrainment of murine circadian oscillators. PLoS One (2013) 0.84
The role of clock in ethanol-related behaviors. Neuropsychopharmacology (2013) 0.84
The circadian clock, reward, and memory. Front Mol Neurosci (2011) 0.83
Even a stopped clock tells the right time twice a day: circadian timekeeping in Drosophila. Pflugers Arch (2007) 0.83
Circadian genes differentially affect tolerance to ethanol in Drosophila. Alcohol Clin Exp Res (2013) 0.82
Ethological analyses of crayfish behavior: a new invertebrate system for measuring the rewarding properties of psychostimulants. Behav Brain Res (2004) 0.81
Amines and motivated behaviors: a simpler systems approach to complex behavioral phenomena. J Comp Physiol A Neuroethol Sens Neural Behav Physiol (2005) 0.80
The circadian system is a target and modulator of prenatal cocaine effects. PLoS One (2007) 0.80
Glia in Drosophila behavior. J Comp Physiol A Neuroethol Sens Neural Behav Physiol (2014) 0.80
I Believe I Can Fly!: Use of Drosophila as a Model Organism in Neuropsychopharmacology Research. Neuropsychopharmacology (2015) 0.79
Cocaine affects foraging behaviour and biogenic amine modulated behavioural reflexes in honey bees. PeerJ (2014) 0.79
Minutes, days and years: molecular interactions among different scales of biological timing. Philos Trans R Soc Lond B Biol Sci (2014) 0.79
Persistent gene expression changes in ventral tegmental area of adolescent but not adult rats in response to chronic nicotine. Neuroscience (2010) 0.79
Altered expression of circadian clock gene, mPer1, in mouse brain and kidney under morphine dependence and withdrawal. J Circadian Rhythms (2006) 0.78
Assessing ethanol's actions in the suprachiasmatic circadian clock using in vivo and in vitro approaches. Alcohol (2014) 0.78
Do circadian genes and ambient temperature affect substrate-borne signalling during Drosophila courtship? Biol Open (2015) 0.77
Addiction and the adrenal cortex. Endocr Connect (2013) 0.76
Molecular clocks (joint Juan March/EMBO workshop). Madrid, May 10-12, 1999. EMBO J (2000) 0.75
Implications of circadian rhythm and stress in addiction vulnerability. F1000Res (2016) 0.75
Drosophila Clock Is Required in Brain Pacemaker Neurons to Prevent Premature Locomotor Aging Independently of Its Circadian Function. PLoS Genet (2017) 0.75
Genetics and genomics of alcohol responses in Drosophila. Neuropharmacology (2017) 0.75
Clock Genes in Glia Cells: A Rhythmic History. ASN Neuro (2016) 0.75
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
The Drosophila ninaE gene encodes an opsin. Cell (1985) 3.65
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
The cloned dopa decarboxylase gene is developmentally regulated when reintegrated into the Drosophila genome. Cell (1983) 3.08
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation (1996) 2.69
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med (1972) 2.60
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44
Establishing a therapeutic range for heparin therapy. Ann Intern Med (1993) 2.31
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med (1989) 2.28
Managing oral anticoagulant therapy. Chest (2001) 2.25
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 2.23
Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med (1973) 2.17
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 2.14
Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost (2015) 2.07
Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med (1981) 2.04
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.01
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol (1966) 1.94
Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med (2001) 1.93
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest (1985) 1.92
Ectopic G-protein expression in dopamine and serotonin neurons blocks cocaine sensitization in Drosophila melanogaster. Curr Biol (2000) 1.90
A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation (1995) 1.90
Interactions of warfarin with drugs and food. Ann Intern Med (1994) 1.88
Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet (1970) 1.84
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med (1991) 1.81
A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med (1998) 1.76
The antidepressant-sensitive dopamine transporter in Drosophila melanogaster: a primordial carrier for catecholamines. Mol Pharmacol (2001) 1.73
A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med (1999) 1.72
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2000) 1.71
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med (1986) 1.67
Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems. Br Med J (1968) 1.66
Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography. N Engl J Med (1977) 1.66
Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med (1982) 1.64
The trace amine tyramine is essential for sensitization to cocaine in Drosophila. Curr Biol (1999) 1.60
Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption. Can Med Assoc J (1976) 1.59
The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med (1998) 1.58
Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost (1989) 1.58
Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost (2001) 1.58
Reevaluation of the sensitivity of impedance plethysmography for the detection of proximal deep vein thrombosis. Arch Intern Med (1994) 1.56
Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study. CMAJ (1999) 1.52
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med (1983) 1.51
Binding of a Drosophila POU-domain protein to a sequence element regulating gene expression in specific dopaminergic neurons. Nature (1990) 1.51
Regulated splicing produces different forms of dopa decarboxylase in the central nervous system and hypoderm of Drosophila melanogaster. EMBO J (1986) 1.50
Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation (1976) 1.50
The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study. Thromb Haemost (1998) 1.49
Increased platelet adhesiveness in recurrent venous thrombosis and pulmonary embolism. Br Med J (1965) 1.48
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med (1996) 1.45
The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest (2001) 1.45
Molecular mapping of a gene cluster flanking the Drosophila Dopa decarboxylase gene. Genetics (1984) 1.44
Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost (1995) 1.44
Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch Intern Med (1998) 1.43
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. J Clin Invest (1978) 1.43
Heparin in the treatment of venous thrombo-embolic disease: administration, control and results. Med J Aust (1968) 1.41
Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med (1995) 1.41
Conserved and sexually dimorphic behavioral responses to biogenic amines in decapitated Drosophila. Proc Natl Acad Sci U S A (1997) 1.41
Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. J Lab Clin Med (1998) 1.40
The cuticle genes of drosophila: a developmentally regulated gene cluster. Cell (1981) 1.39
The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med (1988) 1.39
Inadequate monitoring of warfarin dosage. Blood (1992) 1.38
Embryonic expression pattern of a family of Drosophila proteins that interact with a central nervous system regulatory element. Genes Dev (1989) 1.38
Prevalence of neural tube defects in United States Army treatment facilities, 1975-1985; cost analysis of routine screening. Mil Med (1988) 1.38
Stereotypic behavioral responses to free-base cocaine and the development of behavioral sensitization in Drosophila. Curr Biol (1998) 1.37
Resolution of acute massive pulmonary embolism after pulmonary arterial infusion of streptokinase. Lancet (1967) 1.37
Characterization of the stress-inducing effects of homocysteine. Biochem J (1998) 1.34
Clinical experience with anticoagulant therapy during pregnancy. Br Med J (1970) 1.34
A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest (1990) 1.32
The araC promoter: transcription, mapping and interaction with the araBAD promoter. Cell (1977) 1.31
Thrombo-embolism and increased platelet adhesiveness in post-splenectomy thrombocytosis. Australas Ann Med (1966) 1.29
Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med (2001) 1.28
Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med (1993) 1.26
High resolution electron microscopic studies of genetic regulation. J Mol Biol (1976) 1.26
Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet (1987) 1.25
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1995) 1.24
Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med (1998) 1.24
CNS and hypoderm regulatory elements of the Drosophila melanogaster dopa decarboxylase gene. Science (1986) 1.23
In vitro and in vivo functions of thrombin-treated platelets. Thromb Haemost (1976) 1.22
The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost (1989) 1.22
In vivo experiments on the mechanism of action of L-arabinose C gene activator and lactose repressor. J Mol Biol (1973) 1.22
Is the dose of warfarin prescribed by American physicians unnecessarily high? Arch Intern Med (1987) 1.21